Octapharma France in the news
Plasma, medicine, patients, lives
Tamtam found 10 recent articles about Octapharma France.
- Octapharma refond le système de surveillance de son usine de Lingolsheim
Modernization of the Lingolsheim plant's monitoring systems to improve maintenance responsiveness and ensure strict environmental compliance for plasma-derived medicine production.
- Lingolsheim. Jusqu’où ira Octapharma ?
Octapharma's Lingolsheim facility is undergoing rapid industrial expansion and production increases despite ongoing legal opposition from local neighborhood associations.
- Octapharma : une bonne dose d’innovation en remède à la crise – L’interview de Fanny Chauvel
Implementation of a 140 million euro investment plan at the Lingolsheim site to automate production lines and hire 50 new employees.
- Mobilité | Ambassadeur vélo en entreprise. Lingolsheim : Octapharma veut faire grandir sa communauté de cyclistes
Octapharma's Lingolsheim facility is promoting cycling culture and won a regional commuting challenge thanks to an internal bicycle ambassador program.
- Le groupe pharmaceutique Octapharma investit 80 millions d'euros en Alsace
Octapharma is investing 80 million euros to double production capacity of blood plasma-based immunotherapies at its Lingolsheim site for the US market.
- Industrie pharmaceutique | Un investissement de 120 millions d’euros. Octapharma s’agrandit à Lingolsheim
Octapharma is investing 120 million euros to expand its human blood plasma medicine production site in Lingolsheim.
- Octapharma investit 85 millions d'euros à Lingolsheim
An 85 million euro investment at the Lingolsheim site will double human protein production capacity to 12 tons per year by 2024.
- Industrie pharmaceutique. Lingolsheim : Octapharma s’agrandit
Octapharma is expanding its global production of plasma-derived medicines for various therapeutic areas.
- Lingolsheim - Octapharma. Des riverains opposés à l’extension
Local residents are legally challenging the expansion of the Octapharma production plant in Lingolsheim due to urban integration concerns.
- La marchandisation du sang en ordre de marche
A 2014 Council of State decision classified plasma SD as a medicine, allowing its commercialization by companies like Octapharma and ending the French Blood Establishment's monopoly.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Octapharma France?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies